- Reaction score
- 614
Topically is a challenge because of the sheer size, it just wouldn't penetrate the skin. Local injection would be ideal though surely
Bayer Prolactin Receptor Antibody For Male And Female Pattern Hair Loss
- Thread starter Ollie
- Start date
Topically is a challenge because of the sheer size, it just wouldn't penetrate the skin. Local injection would be ideal though surely
No, it would require a hundred injections. It's so much easier to take one injection in the abdomen. Besides, how else are you going to shrink your prostate and kill cancer? It has so many benefits besides hair growth, you want all of them.
- Reaction score
- 453
Wait, so.it Will come as belly injection?
Last edited:
One systemic injection
- Reaction score
- 453
Interesting. I wonder if they are already studying possible side effets
This is literally the goal of clinical trials lol. They've completed phase 1.
They already conducted a phase 1 safety trial, and said it's very safe.
- Reaction score
- 614
The belly injection was for endometriosis trials
- Reaction score
- 342
You're saying the method is different for Androgenetic Alopecia?
- Reaction score
- 614
We haven't seen the method for androgenic alopecia
It's in the patent. A single abdominal injection
- Reaction score
- 453
Any news on phase 3?
They are preparing phase 2 in USA, Germany and China. But there is probably more infos in previous pages.
- Reaction score
- 984
Could you please tell me:
Where do you get the info that the prepare phase 2 in Germany?
Please give me the source of that
Thanks!
Hope Medicine Inc. Announced Dr. Henri Nico Doods as President and Head of Research & Clinical Development - PR Newswire APAC
SHANGHAI, Dec. 14, 2020 /PRNewswire/ -- Hope Medicine Inc. Announced Dr. Henri Nico Doods as President and Head of Research & Clinical Development
en.prnasia.com
" For HMI-115, the company is planned to launch a globally integrated phase II clinical study in Europe, the United States and China in 2021. At the same time, in response to unmet clinical needs, HopeMed established a diversified pipeline through License-in and independent research and development of dual-drive models. In addition to HMI-115, based on Professor Xiao's breakthrough research at the IMM, the target drug, MG53 will be introduced from Peking University, which showed a good therapeutic effect on diabetes and diabetic foot animal models."
Maybe not Germany, but Europe though. It took me 1 minute to find it. You could have made an effort. It doesn't matter where it is in Europe, medication's reglementation is harmonized by EMA in E.Union.
Hope Medicine Inc. Dr. Henri Nico Doods as President and Director of Clinical Research and Development - New Journal
SHANGHI, December 14, 2020 / PRNewswire / - Hope Medicine Inc. ('HopeMed') is a state-of-the-art global biopharmaceutical company. HopeMed recently announcedArray. .
newjournal.net
"HMI. 115, a prolactin anti-receptor antibody, has passed animal experiments and Phase I clinical studies in humans. Array and will participate in Phase II trials on multiple indications in 2021. I am pleased to enroll in this perfect superior prospective team, I am committed and motivated to facilitate the company’s built-in global Phase II clinical studies in Europe, the United States and China, and to advance strategic plans for the structure of a pipeline of high quality projects in the future."
- Reaction score
- 984
Hope Medicine Inc. Announced Dr. Henri Nico Doods as President and Head of Research & Clinical Development - PR Newswire APAC
SHANGHAI, Dec. 14, 2020 /PRNewswire/ -- Hope Medicine Inc. Announced Dr. Henri Nico Doods as President and Head of Research & Clinical Development
" For HMI-115, the company is planned to launch a globally integrated phase II clinical study in Europe, the United States and China in 2021. At the same time, in response to unmet clinical needs, HopeMed established a diversified pipeline through License-in and independent research and development of dual-drive models. In addition to HMI-115, based on Professor Xiao's breakthrough research at the IMM, the target drug, MG53 will be introduced from Peking University, which showed a good therapeutic effect on diabetes and diabetic foot animal models."
Maybe not Germany, but Europe though. It took me 1 minute to find it. You could have made an effort. It doesn't matter where it is in Europe, medication's reglementation is harmonized by EMA in E.Union.
Hope Medicine Inc. Dr. Henri Nico Doods as President and Director of Clinical Research and Development - New Journal
SHANGHI, December 14, 2020 / PRNewswire / - Hope Medicine Inc. ('HopeMed') is a state-of-the-art global biopharmaceutical company. HopeMed recently announcedArray. .
"HMI. 115, a prolactin anti-receptor antibody, has passed animal experiments and Phase I clinical studies in humans. Array and will participate in Phase II trials on multiple indications in 2021. I am pleased to enroll in this perfect superior prospective team, I am committed and motivated to facilitate the company’s built-in global Phase II clinical studies in Europe, the United States and China, and to advance strategic plans for the structure of a pipeline of high quality projects in the future."
I know this sources But my question was Where it is mentioned that they trial in germany.
But thanks For your effort to offend me.
Bayer is based in Germany, and that's where phase I was conducted iirc
Yeah, the fact that they said the hairline moved forward significantly should be a really good indicator of efficacy.
You can find the endometriosis study on PubMed. I don't think they did a specific study for Androgenetic Alopecia so it still hasn't been tried in a human male.
Isn't a phase 1 only a toxicity test ?